KALA BIO, Inc. (KALA)
NCM · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About KALA BIO, Inc.
KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment. Its platform intends to utilize the KPI-012 clinical development dataset as a proof-of-concept validation environment, as well as the mesenchymal stem cell secretome (MSC-S) and persistent corneal epithelial defects (PCED) research for agentic workflows on trial data. The company serves biotechnology and pharmaceutical companies. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -10.3M | -10.2M | -10.2M | -1.8M |
| Net Income | -11.2M | -7.6M | 686K | -1.6M |
| Diluted EPS | $-85.50 | $-53.50 | $nan | $-7.00 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 3.9M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.3M | 0.00 | ||
| Operating Income | -81.4M | -34.3M | -34.2M | -39.0M |
| Net Income | -44.8M | -42.2M | -38.5M | -27.0M |
| Diluted EPS | $-1,474.00 | $-867.50 | $-507.50 | $-165.50 |